Sign inJoin waitlistJoin the waitlist

DK

Danielle Krol

Physician · Jupiter Medical Center

Credentials: · · · · ·

History

Jupiter Medical Center
2026–Present

Medical Oncology
2015–2017
Internal Medicine
2012–2015
Doctor of Medicine
2008–2012

Research

U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review
Review · Clinical Cancer Research · 2022 · 60 citations
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic…
Journal of Clinical Oncology · 2024 · 43 citations
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus…
The Lancet Oncology · 2021 · 30 citations

JG
Jennifer Gao
5 papers
RP
Richard Pazdur
5 papers
CO
Christy Osgood
4 papers
GI
Gwynn Ison
4 papers
JB
Julia Beaver
4 papers
MR
Melanie Royce
3 papers
MS
Mirat Shah
3 papers
PK
Paul Kluetz
3 papers
SW
Suparna Wedam
3 papers
CB
Christina Brus
2 papers
DS
Daniel Suzman
2 papers
Tara Berman
2 papers

Clinical trials

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Site PI · Recruiting
Natera, Inc.
2026–2037
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2024–2030
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034